Migration notice:
On August 9th, 2025, Finsight.com market data will be renamed and migrated to CreditFlow, a more intuitive, comprehensive and accessible market data platform for all credit products.
Contact us
for more information.
Market Data
Pricing
Solutions
Log In
Market Overview
Parent Companies
DRI Capital Inc
Drug Royalty LP
Drug Royalty LP
ABS
HYC
IGC
APAC
EMEA
LATM
USOA
Deals
Pulled
In Market
Priced
C/P
Sector
Status
Deal Name
Parent
Leads
Region
Date
ABS
ESOT
PRCD
DRUG 2018-1 (USD 100m)
DRI Capital Inc
GSC
USOA
Nov 30, 2018
Class
CCY
SIZE (M)
WAL
MO
SP
FI
DR
KR
C/E
LTV
TYPE
BNCH
IPT
GDNC
SPRD
CPN
YLD
PRICE
C1
OUW
18.000
7.69
-
QQQ
-
-
OOO
-
-
Qeowqkyr
3dT
-
-
160
3mI+160
-
323.00000
G2
TKC
44.000
3.61
-
SSS
-
-
RRR
-
-
-
-
-
-
-
4.27%
4.300%
64.16767
Filings
ABS-15G
Tranche Comments
C1: Registration: 144Z Cmxy; G2: Registration: 144X Mmkt;
ABS
ESOT
PRCD
DRUG 2017-1 (USD 150m)
DRI Capital Inc
GSC
USOA
Jun 5, 2017
ABS
ESOT
PRCD
DRUG 2016-1 (USD 145m)
DRI Capital Inc
GSC
USOA
Jun 3, 2016
ABS
ESOT
PRCD
DRUG 2014-1 (USD 450m)
DRI Capital Inc
GSC
,
BAM
USOA
Jun 18, 2014
ABS
ESOT
PRCD
DRUG 2012-1 (USD 220m)
DRI Capital Inc
GSC
USOA
Nov 30, 2012
ABS
ESOT
PRCD
DRUG 2012-1 (USD 195m)
DRI Capital Inc
CSG
USOA
Mar 21, 2012
Commentary
Upgrade Plan
Deal Flow
Upgrade Plan
B&I
BWICS & Inventory
This module is available on the Professional plan.
Learn more
Upgrade Plan
TRACE
This module is available on the Professional plan.
Learn more
Upgrade Plan
Research
Log In
Missing something? Tell us.